Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 11/2016

20.09.2016 | Review

Natural products against cancer angiogenesis

verfasst von: El Bairi Khalid, EL-Meghawry EL-Kenawy Ayman, Heshu Rahman, Guaadaoui Abdelkarim, Agnieszka Najda

Erschienen in: Tumor Biology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

The process of angiogenesis is quite well-known nowadays. Some medicines and extracts affecting this process are already used routinely in supporting the conventional treatment of many diseases that are considered angiogenic such as cancer. However, we must be aware that the area of currently used drugs of this type is much narrower than the theoretical possibilities existing in therapeutic angiogenesis. Plant substances are a large and diverse group of compounds that are found naturally in fruits, vegetables, spices, and medicinal plants. They also have different anticancer properties. The aim of this literature review article is to present the current state of knowledge concerning the molecular targets of tumor angiogenesis and the active substances (polyphenols, alkaloids, phytohormones, carbohydrates, and terpenes) derived from natural sources, whose activity against cancer angiogenesis has been confirmed.
Literatur
1.
2.
Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:359–86.CrossRef
3.
4.
Davis EL. Oh B, Butow PN, Mullan BA, Clarke S. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist. 2012;17:1475–81.PubMedPubMedCentralCrossRef
5.
Harvey AL, Edrada-Ebel RA, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nature Rev. Drug Discov. 2015;14(2):111–29.CrossRef
6.
Wang CZ, He H, Wang X, Yuan CS. Trends in scientific publications of Chinese medicine. Am J Chin Med. 2012;40:1099–108.PubMedCrossRef
7.
Bell RMA. Review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs. 2010;14:365–70.PubMedCrossRef
8.
9.
Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109:3012–43.PubMedCrossRef
10.
Lenzi P, Bocci G, Natale G. John Hunter and the origin of the term “angiogenesis”. Angiogenesis. 2016; 1–2.
11.
12.
Distler JW, Hirth A, Kurowska-Stolarska M, Gay RE, Gay S, Distler O. Angiogenic and angiostatic factors in the molecular control of angiogenesis. Q J Nucl Med. 2003;47:149–61.PubMed
13.
Kinja K, Rohit S, Mandloi A, Sharma I, Savita S. Anti-angiogenic therapy—past, present and future. Rec Res Sci Tech. 2001;3:8–15.
14.
Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett. 2012;320:130–7.PubMedCrossRef
15.
Zielonka TM. Angiogeneza – Część I. Mechanizm powstawania nowych naczyń krwionośnych. Alerg Astma Immun. 2003;8:169–74.
16.
King A, Balaji S, Keswani SG, Crombleholme TM. The role of stem cells in wound angiogenesis. Adv Wound Care (New Rochelle). 2014;3:614–25.CrossRef
17.
Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Kąt N, Cheresh DA. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809–13.PubMedPubMedCentralCrossRef
18.
Kurzyk A. Angiogenesis—the possibilities, problems and prospects. Progress Biochemistry. 2015;61(1):25–34 [in Polish].
19.
Watt SM, Athanassopoulos A, Harris AL. Human endothelial stem/progenitor cells, angiogenic factors and vascular repair. J R Soc Interface. 2010;7(6):731–51.CrossRef
20.
Wiśniewski T, Makarewicz R, Ziółkowska E, Rystok D, Zekannowska E. Angiogeneza nowotworowa – mechanizmy, czynniki regulujące, leki. Onkologia Info. 2009;6(5):172–8.
21.
Namiecińska M, Marciniak K, Nowak JZ. VEGF jako czynnik angiogenny, neurotroficzny i neuroprotekcyjny. Postepy Hig Med Dośw. 2005;59:573–83.
22.
Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature Rev Drug Discov. 2007;6:273–86.CrossRef
23.
Siemerink MJ, Augustin AJ, Schlingemann RO. Mechanisms of ocular angiogenesis and its molecular mediators. Dev Ophthalmol. 2010;46:4–20.PubMedCrossRef
24.
25.
Shahneh FZ, Baradaran B, Zamani F, Aghebati-Maleki L. Tumor angiogenesis and anti-angiogenic therapies. Hum Antibodies. 2013;22:15–9.PubMed
26.
Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci. 2007;104:967–72.PubMedPubMedCentralCrossRef
27.
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17(3):471–94.PubMedPubMedCentralCrossRef
28.
Swift MR, Weinstein BM. Arterial-venous specification during development. Circ Res. 2009;104:576–88.PubMedCrossRef
29.
Herbert SP, Stainier DY. Molecular control of endothelial cell behavior during blood vessel morphogenesis. Nat Rev Mol Cell Biol. 2011;12:551–64.PubMedPubMedCentralCrossRef
30.
Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, Wolburg H, Betsholtz C. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543–53.PubMedPubMedCentralCrossRef
31.
Ferrara N, Gerber HP. The biology of VEGF and its receptors. J Nat Med. 2003;9:669–76.CrossRef
32.
33.
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401–10.PubMedCrossRef
34.
35.
Zhang J, Li Y. Therapeutic uses of FGFs. Semin Cell Dev Biol. 2015:S1084–9521 (15)00166-4.
36.
Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12(2):125–37.PubMedCrossRef
37.
Kappou D, Sifakis S, Konstantinidou A, Papantoniou N, Spandidos DA. Role of the angiopoietin/Tie system in pregnancy (review). Exp Ther Med. 2015;9(4):1091–6.PubMedPubMedCentral
38.
Khan KA, Bicknell R. Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis. 2016;33:197–210.PubMedCrossRef
39.
Holderfield MT, Hughes CCW. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res. 2008;102:637–52.PubMedCrossRef
40.
Roedersheimer M et al. A bone-derived mixture of TGFβ-superfamily members forms a more mature vascular network than bFGF or TGF-β2 in vivo. Angiogenesis. 2006;8(4):327–38.CrossRef
41.
42.
Umikawa M, Umikawa A, Asato T, Takei K, Matsuzaki G, Kariya K, Zhang CC. Angiopoietin-like protein 2 induces proinflammatory responses in peritoneal cells. Biochem Biophys Res Commun. 2015;467(2):235–41.PubMedPubMedCentralCrossRef
43.
Wagner M et al. Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis. Angiogenesis. 2012;15(3):481–95.PubMedPubMedCentralCrossRef
44.
Phng LK, Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell. 2009;16(2):196–208.PubMedCrossRef
45.
Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007;21(20):2511–24.PubMedCrossRef
46.
Sainson RCA, Harris AL. Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies. Angiogenesis. 2008;11(1):41–51.PubMedCrossRef
47.
Gorantla B et al. Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma. Angiogenesis. 2013;16(1):85–100.PubMedCrossRef
48.
Serini G, Maione F, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis. 2009;12(2):187–93.PubMedCrossRef
49.
50.
Geretti E, Shimizu A, Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis. 2008;11(1):31–9.PubMedCrossRef
51.
Staton CA. Class 3 semaphorins and their receptors in physiological and pathological angiogenesis. Biochem Soc Trans. 2011;39:1565–70.PubMedCrossRef
52.
Leszczynska K, Kaur S, Wilson E, Bicknell R, Heath VL. The role of RhoJ in endothelial cell biology and angiogenesis. Biochem Soc Trans. 2011;39:1606–11.PubMedCrossRef
53.
54.
55.
Zhuang X, Cross D, Heath VL, Bicknell R. Shear stress, tip cells and regulators of endothelial migration. Biochem Soc Trans. 2011;39:1571–5.PubMedCrossRef
56.
Francis ME, Uriel S, Brey EM. Endothelial cell-matrix interactions in neovascularization. Tissue Eng Part B Rev. 2008;14(1):19–32.PubMedCrossRef
57.
Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):512–23.PubMedCrossRef
58.
Laurenzana A, Fibbi G, Margheri F, Biagioni A, Luciani C, Del Rosso M, Chillà A. Endothelial progenitor cells in sprouting angiogenesis: proteases pave the way. Curr Mol Med. 2015;15(7):606–20.PubMedCrossRef
59.
Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol. 2003;161(6):1163–77.PubMedPubMedCentralCrossRef
60.
Makanya AN, Hlushchuk R, Djonov VG. Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. Angiogenesis. 2009;12:113–23.PubMedCrossRef
61.
Gianni-Barrera R et al. VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. Angiogenesis. 2013;16(1):123–36.PubMedCrossRef
62.
VanHinsbergh VW, Koolwijk P. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res. 2008;78(2):203–12.CrossRef
63.
Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomaki A, Aranda E, Miura N, Yla-Herttuala S, Fruttiger M, Makinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing notch signalling. Nat Cell Biol. 2011;13:1202–13.PubMedPubMedCentralCrossRef
64.
65.
Fresco P, Borges F, Diniz C, Marques MPM. New insights on the anticancer properties of dietary polyphenols. Med Res Rev. 2006;26(6):747–66.PubMedCrossRef
66.
Lau ST, Lin ZX, Zhao M, Leung PS. Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytother Res. 2008;22:477–86.PubMedCrossRef
67.
Lee RT, Hlubocky F, Hu JJ, Stafford R, Daugherty C. An international pilot study of oncology physicians? Opinions and practices on complementary and alternative medicine (CAM). Integr Cancer Ther. 2008;7(2):70–5.PubMedCrossRef
68.
Lee SM, Kwon JI, Choi YH, Eom HS, Chi GY. Induction of G2/M arrest and apoptosis by water extract of Strychni semen in human gastric carcinoma AGS cells. Phytother Res. 2008;22(6):752–8.PubMedCrossRef
69.
Yeh JC, Cindrova-Davies T, Belleri M, Morbidelli L, Miller N, Cho CW, Chan K, Wang YT, Luo GA, Ziche M, Presta M, Charnock-Jones DS, Fan TP. The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. Angiogenesis. 2011;14(2):187–97.PubMedCrossRef
70.
Rasul A, Yu B, Khan M, Zhang K, Iqbal F, Ma T, Yang H. Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. Int J Oncol. 2012;40(4):1153–61.PubMed
71.
Lumlerdkij N et al. Cytotoxicity of medicinal plants used in cancer prevention in Thailand. Planta Med. 2015;81(16) PW_31.
72.
Mehta HJ, Patel V, Sadikot RT. Curcumin and lung cancer—a review. Target Oncol. 2014;9(4):295–310.PubMedCrossRef
73.
de Vogel S, Dindore V, van Engeland M, Goldbohm RA, van den Brandt PA, Weijenberg MP. Dietary folate, methionine, riboflavin, and vitamin B-6 and risk of sporadic colorectal cancer. J Nutr. 2008;138:2372–8.PubMedCrossRef
74.
75.
Danciu C, Avram S, Gaje P, Pop G, Şoica C, Craina M, Dumitru C, Dehelean C, Peev C. An evaluation of three nutraceutical species in the Apiaceae family from the western part of Romania: antiproliferative and antiangiogenic potential. J Agroalimentary Processes Technol. 2013;19(2):173–9.
76.
Sauer, Heinrich, et al. Herbal ingredients for the inhibition of tumour-induced angiogenesis. Botanical Medicine in Clinical Practice. 2008. p. 335.
77.
Carvalho AA, Costa PMD, Vieira GC, Jamacaru FVF, Moraes MO, Cavalcanti BC, Pessoa C. Natural products used as candidates for angiogenesis inhibitors in cancer therapy. Trends Org Chem. 2011;15:79–93.
78.
Dudkowska M, Kucharewicz K. Natural compounds—modulators of senescence and cell death. Postępy Biochemii. 2014;60(2):207–20.PubMed
79.
Lin W, Zhao J, Cao Z, Zhuang Q, Zheng L, Zeng J, Hong Z, Peng J. Livistona chinensis seeds inhibit hepatocellular carcinoma angiogenesis in vivo via suppression of the Notch pathway. Oncol Rep. 2014;31:1723–8.PubMed
80.
81.
Jennifer AD, Jennifer EH, Gerald EH. Role of apoptosis in anti-angiogenic cancer therapies. In: Gewirtz DA, Holt SE, Grant S, editors. Apoptosis, senescence and cancer. New York: Humana Press Inc.; 2007. p. 537–56.
82.
Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Am Assoc Cancer Res. 2014;8(26):1–27.
83.
Ludwiczuk A, Najda A, Wolski T, Baj T. Chromatographic determination of the content and the composition of extracts and essential oils from the fruits of three varieties of stalk celery (Apium graveolens L. var dulce Mill. Pers.). JPC-J Planar Chromat. 2001;14(6):400–4.
84.
Buczkowska H, Dyduch J, Najda A. Capsaicinoids in hot pepper depending on fruit maturity stage and harvest date. Acta Sci Pol-Hortorum Cultus. 2013;6:183–96.
85.
Kapłan M, Najda A. Antioxidant activity of vine fruits depending on their colouring. Chemija. 2014;25(1):51–5.
86.
Chinembiri TN, du Plessis LH, Gerber M, Hamman JH, du Plessis J. Review of natural compounds for potential skin cancer treatment. Molecules. 2014;19:11679–721.PubMedCrossRef
87.
Najda A, Dyduch-Siemińska M, Dyduch J, Gantner M. Comparative analysis of secondary metabolites contents in Fragaria vesca L. fruits. Ann Agric Envir Med. 2014;21(2):339–43.CrossRef
88.
Najda A, Dyduch J, Świca K, Kapłan M, Papliński R, Sachadyn-Król M, Klimek K. Identification and profile of furanocoumarins from the ribbed celery (Apium graveolens L. Var. dulce mill. / Pers.). Food Sci Tech Res. 2015;21(1).
89.
Najda A. Toxic substances in plants with built structure with nitrogen. Episteme. 2014;25(1):65–76.
90.
Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39:283–99.PubMedPubMedCentralCrossRef
91.
92.
Qiu Y, Yu T, Wang W, Pan K, Shi D, Sun H. Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. BiochemBiophys Res Commun. 2014;448:15–21.CrossRef
93.
Martinez RM, Pinho-Ribeiro FA, Steffen VS, Silva TC, Caviglione CV, Bottura C, Fonseca MJ, Vicentini FT, Vignoli JA, Baracat MM, Georgetti SR, Verri Jr WA, Casagrande R. Topical formulation containing naringenin: efficacy against ultraviolet b irradiation-induced skin inflammation and oxidative stress in mice. PLoS One. 2016;11(1). doi:10.​1371/​journal.​pone.​0146296.
94.
Surh YJ. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: a short review. Food Chem Toxicol. 2002;40(8):1091–7.PubMedCrossRef
95.
Najda A, Błaszczyk L, Winiarczyk K, Dyduch J, Tchórzewska D. Comparative studies of nutritional and health-enhancing properties in the “garlic-like” plant Allium ampeloprasum var. ampeloprasum (GHG-L) and A. sativum. Sci Horticulturae. 2016;201:247–55.CrossRef
96.
Yesil-Celiktas O, Sevimli C, Bedir E, Vardar-Sukan F. Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines. Plant Foods HumNutr. 2010;65:158–63.CrossRef
97.
Petiwala SM, Berhe S, Li G, Puthenveetil AG, Rahman O, Nonn L, Johnson JJ. Rosemary (Rosmarinus officinalis) extract modulates CHOP/GADD153 to promote androgen receptor degradation and decreases xenograft tumor growth. PLoS One. 2014;9:e89772.PubMedPubMedCentralCrossRef
98.
Kwon H.J., Shim J.S., Kim J.H., Cho H.Y., Yum Y.N., Kim S.H., Yu J. Betulinic acid inhibits growth factor-induced angiogenesis via the modulation of mitochondrial function in endothelial cells. Jpn J Cancer Res 2002; 93(4): 417–425.
99.
Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S. Inhibition of angiogenesis by humulone; a bitter acid from beer hop. Biochem.Biophys. Res. Commun. 2001;289(1):220–4.PubMedCrossRef
100.
Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci. 2011;1215:1–8.PubMedCrossRef
101.
Shen T, Xie CF, Wang XN, Luo HX. Stilbenoids. In: Ramawat KG, Merillon JM, editors. Natural products. Berlin: Springer; 2013. p. 1901–49.CrossRef
102.
Foitzik T, Hotz HG, Hotz B, Wittig F, Buhr HJ. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepato-Gastroenterology. 2003;50(52):1159–62.PubMed
103.
Höper MM, Voelkel NF, Bates TQ, Allard JD, Horan M, Shepherd D, Tudier R. Prostaglandin induce VEGF growth factor in human monocytic cell lines and rat lungs via cAMP. Am J Respir Cell Mol Biol. 1997;17(6):748–56.PubMedCrossRef
104.
Li T, Hu J, Du S, Chen Y, Wang S, Wu Q. ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. Mol Vis. 2014;20:1109–21.PubMedPubMedCentral
105.
Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging function on cell proliferation and angiogenesis: implication for cancer therapy. FASEB J. 2003;17(14):1986–95.PubMedCrossRef
106.
107.
Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ. Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. Am Soc Clin Oncol. 2006;24(34):5457–64.CrossRef
108.
Castillo-Pichardo L, Dharmawardhane SF. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer. Nutr Cancer. 2012;64:1058–69.PubMedPubMedCentralCrossRef
109.
Huang S et al. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling. Nutr Res. 2012;32(7):530–6.PubMedCrossRef
110.
Taraphdar AK, Roy M, Bhattacharya RK. Natural products as inducers of apoptosis: implication for cancer therapy and prevention. Current Sci. 2001;80:1387–96.
111.
Molassiotis A, Fernandez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655–63.PubMedCrossRef
112.
Loboda A, Cisowaski J, Zarebski A, Jazwa A, Rivera Nunez D, Kyprotakis Z, Heinrich M, Dulak J. Effect of plant extracts on angiogenic activities of endothelial cells and keratinomycetes. J Physiol Pharmacol. 2005;1:125–37.
113.
Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Béliveau R. Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res. 2012;318(13):1586–96.PubMedCrossRef
114.
115.
Ribatti D, Nico B, Vacca A, Roncali L, Djonov V. Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and antiangiogenesis in vivo. Ant Rec. 2001;264:317–24.CrossRef
116.
Durupt F, Koppers-Lalic D, Balme B, Budel L, Terrier O, Lina B, Thomas L, Hoeben RC, Rosa-Calatrava M. The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses. Cancer Gene Ther. 2012;19:58–68.PubMedCrossRef
117.
Hsin CH, Wu BC, Chuang CY, Yang SF, Hsieh YH, Ho HY, Lin HP, Chen MK, Lin CW. Selaginella tamariscina extract suppresses TPA-induced invasion and metastasis through inhibition of MMP-9 in human nasopharyngeal carcinoma HONE-1 cells. BMC Complement Altern Med. 2013;13:234–45.PubMedPubMedCentralCrossRef
118.
Yi JM, Park JS, Oh SM, Lee J, Kim J, Oh DS, Bang OS, Kim NS. Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo. BMC ComplementAltern Med. 2012;12:243–51.
119.
Kim EC, Kim SH, Piao SJ, Kim TJ, Bae k, Kim HS, Hong SS, Lee BI, Nam M. Antiangiogenic activity of Acer tegmentosum Maxim water extract in vitro and in vivo. J Korean Med Sci. 2015;30:979–87.PubMedPubMedCentralCrossRef
120.
Najda A. Planning and evaluation of phytochemical plants in various growth phases of two varieties of celery (Apium graveolens L. var dulce Mil./Pers.). 2004; PhD Dissertation, University of Life Sciences in Lublin.
121.
122.
Zhang T, Jia W, Sun X. 3-n-Butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. Neurol Res. 2010;32:390–6.PubMedCrossRef
123.
Tai J, Cheung S, Wu M, Hasman D. Antiproliferation effect of rosemary (Rosmarinus officinalis) on human ovarian cancer cells in vitro. Phytomed. 2012;19:436–43.CrossRef
124.
Petiwala SM, Johnson JJ. Diterpenes from rosemary (Rosmarinus officinalis): defining their potential for anti-cancer activity. Cancer Lett. 2015;367:93–102.PubMedCrossRef
125.
Agostinis P, Vantieghem A, Merlevede W, de Witte PAM. Hypericin in cancer 85 treatment: more light on the way. Int J Biochem Cell Biol. 2002;34:221–41.PubMedCrossRef
126.
Carimi F, Zottini M, Formentin E, Terzi M, Lo Schiavo F. Cytokinins: new apoptotic inducers in plants. Planta. 2003;216:413–21.PubMed
127.
Kuttan G., Pratheeshkumar P., Manu K.A,, Kuttan R. Inhibition of tumor progression by naturally occurring terpenoids. Pharm Biol 2011; 49: 995–1007.PubMedCrossRef
128.
Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. Biotech. 2013;3:439–59.
129.
Parikh NR, Mandal A, Bhatia D, Siveen KS, Sethi G, Bishayee A. Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives. Phytochem Rev. 2014;13:793–810.PubMedPubMedCentralCrossRef
130.
Albini A et al. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9(9):498–509.PubMedCrossRef
131.
Weng CJ, Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treatment Rev. 2012;38:76–87.CrossRef
132.
Beghlal D, El Bairi K, Marmouzi I, Haddar L, Mohamed B. Phytochemical, organoleptic and ferric reducing properties of essential oil and ethanolic extract from Pistacia lentiscus (L.). Asian Pac J Trop Dis. 2016;6(4):305–10.CrossRef
133.
Koohpar ZK, Entezari M, Movafagh A, Hashem M. Anticancer activity of curcumin on human breast adenocarcinoma: role of mcl-1 gene. Iran J Cancer Prev. 2015;8(3):e2331.
134.
Wolanin K, Piwocka K. Curcumin - from natural medicine clinic. Kosmos. 2008;57:53–65.
135.
Kumaravel M, Sankar P, Rukkuma-Ni R. Antiproliferative efect of an analog of curcumin bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione in human breast cancer cells. Eur Rev Med Pharmacol Sci. 2012;16:1900–7.PubMed
136.
Devasena T, Rajasekarana KN, Menon VP. Bis-1,7-(2-hydroxyphenyl)-hepta-1,6-diene-3,5-dione (a curcumin analog) ameliorates DMH-induced hepatic oxidative stressduring colon carcinogenesis. Pharmacol Res. 2002;46:39–45.PubMedCrossRef
137.
Mohankumar K, Pajaniradje S, Sridharan S, Kumar Singh V, Ronsard L, Banerjea AC, Selvanesan Benson C, Selvaraj Coumar M, Rajagopalan R. Mechanism of apoptotic induction in human breast cancer cell, MCF-7, by an analog of curcumin in comparison with curcumin—an in vitro and in silico approach. Chem Biol Interact. 2014;210:51–63.PubMedCrossRef
138.
Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clinic Biochem Nutr. 2007;40:92–100.CrossRef
139.
Ho K, Yazan LS, Ismail N, Ismail M. Apoptosis and cell cycle arrest of human colorectal cancer cell line HT-29 induced by vanillin. Cancer Epidem. 2009;33:155–60.CrossRef
140.
Lirdprapamongkol K, Sakurai H, Kawasaki N, Choo MK, Saitoh Y, Aozukay Y, Singhirunnusorn P, Ruchirawat S, Svasti J, Saiki I. Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. Eur J Pharm Sci. 2005;25:57–65.PubMedCrossRef
141.
Nakazato T, Ito K, Ikeda Y, Kizaki M. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clinic Cancer Res. 2005;11:6040–9.CrossRef
142.
Cheung S, Tai J. Anti-proliferative and antioxidant properties of rosemary Rosmarinus officinalis. Oncol Rep. 2007;17:1525–31.PubMed
143.
Bai N, He K, Roller M, Lai CS, Shao X, Pan MH, Ho CT. Flavonoids and phenolic compounds from Rosmarinus officinalis. J Agric Food Chem. 2010;58:5363–7.PubMedCrossRef
144.
Mulinacci N, Innocenti M, Bellumori M, Giaccherini C, Martini V, Michelozzi M. Storage method, drying processes and extraction procedures strongly affect the phenolic fraction of rosemary leaves: an HPLC/DAD/MS study. Talanta. 2011;85:167–76.PubMedCrossRef
145.
Bernardes WA, Lucarini R, Tozatti MG, Souza MG, Silva ML, Filho AA, et al. Antimicrobial activity of Rosmarinus officinalis against oral pathogens: relevance of carnosic acid and carnosol. Chem Biodivers. 2010;7:1835–40.PubMedCrossRef
146.
147.
Nabekura T, Yamaki T, Hiroi T, Ueno K, Kitagawa S. Inhibition of anticancer drug efflux transporter P-glycoprotein by rosemary phytochemicals. Pharmacol Res. 2010;61:259–63.PubMedCrossRef
148.
Yu YM, Lin CH, Chan HC, Tsai HD. Carnosic acid reduces cytokine-induced adhesion molecules expression and monocyte adhesion to endothelial cells. Eur J Nutr. 2009;48:101–6.PubMedCrossRef
149.
150.
López-Jiménez A, García-Caballero M, Medina MA, Quesada AR. Anti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary. Eur J Nutri. 2013;51(1):85–95.CrossRef
151.
Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC, Gilb B, Kaufmann T, Borner C, Sleeman JP, Simon JC. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John’s wort that acts by induction of apoptosis. Oncogene. 2002;21:1242–50.PubMedCrossRef
152.
Hostanska K, Reichling J, Bommer S, Weber M, Saller R. Hyperforin a constituent of St. John’s wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Eur J Pharm Biopharm. 2003;56:121–32.PubMedCrossRef
153.
Dona M, Dell’Aica I, Pezzato E, Sartor L, Calabrese F, Della Barbera M, Donella-Deana A, Appendino G, Borsarini A, Caniato R, Garbisa S. Hyperforin inhibits cancer invasion and metastasis. Cancer Res. 2004;64:6225–32.PubMedCrossRef
154.
Martínez-Poveda B, Quesada AR, Medina MA. Hyperforin, a bio-active compound of St. John’s wort, is a new inhibitor of angiogenesis targeting several key steps of the process. Inter J Cancer. 2005;17(5):775–80.CrossRef
155.
Aggarwal BB, Bhardwaj A, Aggarwal RS, Steram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783–840.PubMed
156.
Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi M, Sen CK. Anti-angiogenic property of edible berries. Free Radic Res. 2002;36:1023–31.PubMedCrossRef
157.
Pozo-Guisado E, Merino JM, Mulero-Navarro S, Lorenzo-Benayas MJ, Centeno F, Alvarez-Barrientos A, Salguero PMF. Resveratrol-induced apoptosis in Mcf-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-κB. Int J Cancer. 2005;115:74–84.PubMedCrossRef
158.
Kiliańska ZM, Żołnierczyk J, Węgierska-Gądek J. Biological activity of poly (ADP-ribose) -1. Postep. Hig Med Dosw. 2010;64:344–63.
159.
Roy P, Kalra N, Prasad S, George J, Skuhla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharmaceut Res. 2009;26:221–17.CrossRef
160.
Cao Y, Fu ZD, Wang F, Liu HY, Han R. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod Res. 2005;7:205–13.PubMedCrossRef
161.
Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001;171:11–6.PubMedCrossRef
162.
Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of src dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003;64:1029–36.PubMedCrossRef
163.
Kanavi MR, Darjatmoko S, Wang S, Azari AA, Farnoodian M, Kenealey JD, van Ginkel PR, Albert DM, Sheibani N, Polans AS. The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization. Molecules. 2014;19(11):17578–603.PubMedPubMedCentralCrossRef
164.
Zhang H, He S, Spee C, Ishikawa K, Hinton DR. SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by resveratrol and its relevance to choroidal neovascularization. Cytokine. 2001;76(2):549–52.CrossRef
165.
Zhang X, Song Y, Wu Y, et al. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int J Cancer. 2011;129:2502–11.PubMedCrossRef
166.
Vitale DC, Piazza C, Melilli B, Drago F, Salomone S. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet. 2013;38(1):15–25.PubMedCrossRef
167.
168.
169.
Giovannini C, Scazzocchio B, Varì R, Santangelo C, D’archivio M, Masella R. Apoptosis in cancer and atherosclerosis: polyphenol activities. Sanità Ann Ist Super Sanità. 2007;43:406–16.PubMed
170.
Huynh H, Nguyen TT, Chan E, Tran E. Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents transforming growth factor alpha (TGF-α)- and epidermal growth factor (EGF) induced human PC-3 prostate cancer cell proliferation. Int J Oncol. 2003;23:821–9.PubMed
171.
Tan WF, Lin LP, Li MH, Zhang YX, Dong JG, Xiao D, Din J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol. 2003;459:255–62.PubMedCrossRef
172.
O’Leary KA, de Pascual–Tereasa S, Needs PW, Bao YP, O’Brien NM, Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res. 2004;551:245–54.PubMedCrossRef
173.
Dash R, Uddin MM, Hosen SM, Rahim ZB, Dinar AM, Kabir MS, Sultan RA, Islam A, Hossain MK. Molecular docking analysis of known flavonoids as duel COX-2 inhibitors in the context of cancer. Bioinformat. 2015;11(12):543–9.CrossRef
174.
Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH, Huynh H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004;24:1297–304.PubMed
175.
Mojzis J, Varinska L, Mojzisova G, Kostova I, Mirossay L. Anti-angiogenic effects of flavonoids and chalcones. Pharmacol Res. 2008;57(4):259–65.PubMedCrossRef
176.
Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. PNAS. 2008;105:11105–9.PubMedPubMedCentralCrossRef
177.
Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, Sinha R. Cancer incidence rates among south Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2007;37:147–60.PubMedCrossRef
178.
Mense SM, Hei TK, Ganju RK, Bhat HK. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect. 2008;116:426–33.PubMedPubMedCentralCrossRef
179.
Gutierrez RMP. Flavonoids. In: Handbook of compounds with cytotoxic activity isolated from plants. Commack, NY: Nova Science Publishers Inc.; 2007. p. 158–65.
180.
Sharma P, Kapoor S. Biopharmaceutical aspects of Brassica vegetables. J Pharm Phytochem. 2015;4(1):140–7.
181.
Teicher BA. Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res. 2008;14:1610–7.PubMedCrossRef
182.
Katz L, Baltz RH. Natural product discovery: past, present, and future. J Ind Microbiol Biotechnol. 2016;43(2–3):155–76.PubMedCrossRef
183.
Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1997;94:4143–55.
184.
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–24.PubMedPubMedCentralCrossRef
185.
Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res. 2002;8:221–32.PubMed
186.
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.PubMedCrossRef
187.
Stempac D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: applications in pediatric oncology. Cancer Investig. 2006;24:432–43.CrossRef
188.
Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer. 2011;11:124–42.PubMedPubMedCentralCrossRef
189.
Avramis IA, Kwock R, Avramis VI. Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. Anticancer Res. 2001;21(4):2281–6.PubMed
190.
Mabeta P, Pepper MSA. Comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents. Angiogenesis. 2009;12:81–90.PubMedCrossRef
191.
Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M. Beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108:2485–94.PubMedPubMedCentralCrossRef
192.
Grange C, Bussolati B, Bruno S, Fonsato V, Sapino A, Camussi G. Isolation and characterization of human breast tumor-derived endothelial cells. Oncol Rep. 2006;15:381–6.PubMed
193.
Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 2009;15:4838–46.PubMedCrossRef
194.
Polat U. The effects on metabolism of glucosinolates and their hydrolysis products. J Biol Environ Sci. 2010;4(10):39–42.
195.
Chang HK, Shin MS, Yang HY, Lee JW, Kim YS, Lee MH, Kim J, Kim KH, Kim CJ. Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bul. 2006;29:1597–602.CrossRef
196.
Milazzo S, Lejeune S, Ernst E. Laetrile for cancer: a systematic review of the clinical evidence. Suppor Care Cancer. 2007;15:583–95.CrossRef
197.
Hayes JD, Kelleher MO, Eggleston IM. The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Clin Nutr. 2008;47:73–88.CrossRef
198.
Zalega J, Szostak-Węgierek D. Nutrition in cancer prevention. Part I. Plant polyphenols, carotenoids, dietary fiber. ProblHig Epidemiol. 2013;94:41–9.
199.
Kusznierewicz B., Piasek A., Lewandowska J., Śmiechowska A., Bartoszek A., Anti-carcinogenic properties of white cabbage. Żywność Nauka Technologia Jakość 2007; 6: 20–23.
200.
Traka M, Mithen R. Glucosinolates, isothiocyanates and human health. Phytochem Rev. 2009;8:269–82.CrossRef
201.
Casero RA, Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 2007;6(5):373–90.PubMedCrossRef
202.
Zdrojewicz Z, Lachowski M. The importance of putrescine in the human body. Postepy Hig Med Dosw. 2014;68:393–403.CrossRef
203.
Kucharzewska P, Welch JE, Svensson KJ, Belting M. The polyamines regulate endothelial cell survival during hypoxic stress through PI3K/AKT and MCL-1. Biochem Bioph Res. 2009;380(2):413–8.CrossRef
204.
Koomoa DLT, Geerts D, Lange I, Koster J, Pegg AE, Feith DJ, Bachmann AS. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol. 2013;42:1219–28.PubMedPubMedCentral
205.
Jabłońska-Trypuć A, Czerpak R. The role of connective tissue growth factor (CTGF) in fibroproliferative processes and tissues fibrosis. Postepy Biol Komorki. 2009;36:135–54.
206.
Minorsky PV. The hot and the classic. Plant Physiol. 2000;132:1135–6.CrossRef
207.
Ishii Y, Hori Y, Sakai S, Honma Y. Control of diferentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant rediferentiation-inducing hormones. Cell Growth Differ. 2002;13:19–26.PubMed
208.
Kunikowska A, Byczkowska A, Doniak M, Kaźmierczak A. Cytokinins resume: their signaling and role in programmed cell death in plants. Plant Cell Rep. 2013;32:771–80.PubMedPubMedCentralCrossRef
209.
Coltella N, Valsecchi R, Ponente M, Ponzoni M, Bernardi R. Synergistic leukemia eradication by combined treatment with retinoic acid and HIF inhibition by EZN-2208 (PEG-SN38) in preclinical models of PML-RARα and PLZF-RARα-driven leukemia. Clin Cancer Res. 2015;21(16):3685–94.PubMedCrossRef
210.
Liang C, Guo S, Yang L. Effects of all-trans retinoic acid on VEGF and HIF-1α expression in glioma cells under normoxia and hypoxia and its anti-angiogenic effect in an intracerebral glioma model. Mol Med Rep. 2014;10(5):2713–9.PubMed
211.
Aditya NP et al. Antiangiogenic effect of combined treatment with curcumin and genistein on human prostate cancer cell line. J Funct Foods. 2014;8:204–13.CrossRef
212.
Yu X et al. Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation. Med Oncol. 2012;29(1):349–57.PubMedCrossRef
213.
Mirzoeva S, Franzen CA, Pelling JC. Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3-and Src-dependent mechanism. Mol Carcinog. 2014;53(8):598–609.PubMed
214.
Silvan S, Manoharan S. Apigenin prevents deregulation in the expression pattern of cell-proliferative, apoptotic, inflammatory and angiogenic markers during 7, 12-dimethylbenz [a] anthracene-induced hamster buccal pouch carcinogenesis. Arch Oral Biol. 2013;58(1):94–101.PubMedCrossRef
215.
Kumar S, Raina K, Agarwal R. Chemopreventive and anticancer efficacy of silibinin against colorectal cancer, Multi-Targeted Approach to Treatment of Cancer. Berlin Heidelberg New York: Springer; 2015. p. 339–50.
216.
Yang SH, Lin JK, Chen WS, Chiu JH. Yang. Anti-angiogenic effects of silymarin on colon cancer LoVo cell line. J Surg Res. 2003;113(1):133–4l.PubMedCrossRef
217.
Kim KK et al. Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol. 2012;40(1):227–35.PubMed
218.
Wang M-L et al. Antiangiogenic activity of indole-3-carbinol in endothelial cells stimulated with activated macrophages. Food Chem. 2012;134(2):811–20.PubMedCrossRef
219.
Kunimasa K et al. Antiangiogenic effects of indole-3-carbinol and 3,3′-diindolylmethane are associated with their differential regulation of ERK1/2 and Akt in tube-forming HUVEC. J Nutr. 2010;140(1):1–6.PubMedCrossRef
220.
Mohan R et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7(2):115–22.PubMedCrossRef
221.
Hussain S et al. Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis. 2008;11(3):245–56.PubMedCrossRef
222.
Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012;18(12):3428–39.PubMedCrossRef
223.
224.
Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol. 2011;22:2036–41.PubMedCrossRef
225.
Granata R, Locati L, Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Curr Opin Oncol. 2013;25:224–8.PubMed
226.
Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013;14:7. doi:10.​1186/​2050-6511-14-7.PubMedPubMedCentralCrossRef
227.
228.
LoRusso PM, Boerner SA, Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J Clin Oncol. 2011;29(22):2952–5.PubMedCrossRef
229.
230.
Head M, Jameson MB. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Investig Drugs. 2010;19(2):295–304.PubMedCrossRef
231.
Lara, P. N., Douillard, J. Y., Nakagawa, K., Von Pawel, J., McKeage, M. J., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011;JCO-2011.
232.
233.
Lorusso PM, Boerner SA, Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J Clin Oncol. 2011;29(22):2951–2.CrossRef
234.
235.
Tsimberidou AA-MA, Akerley W, Schabel MC, et al. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther. 2010;6827(12):3410–9.CrossRef
236.
Patterson DM, Zweifel M, Middleton MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012;18(5):1415–25.PubMedCrossRef
237.
Burns CJ, Fantino E, Powell AK, et al. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. J Pharmacol Exp Ther. 2011;339(3):799–806.PubMedCrossRef
238.
Burge M, Francesconi AB, Kotasek D, et al. Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular disrupting agent. Investig New Drugs. 2013;31(1):126–35.CrossRef
Metadaten
Titel
Natural products against cancer angiogenesis
verfasst von
El Bairi Khalid
EL-Meghawry EL-Kenawy Ayman
Heshu Rahman
Guaadaoui Abdelkarim
Agnieszka Najda
Publikationsdatum
20.09.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 11/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5364-8

Weitere Artikel der Ausgabe 11/2016

Tumor Biology 11/2016 Zur Ausgabe

Original Article

MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3

Original Article

Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells

Original Article

Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer

Original Article

The anticancer effects of Resina Draconis extract on cholangiocarcinoma

Original Article

Overexpression of IGFBP3 is associated with poor prognosis and tumor metastasis in nasopharyngeal carcinoma

Original Article

Expression and prognostic value of E2F activators in NSCLC and subtypes: a research based on bioinformatics analysis

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

17.04.2024 | Mammakarzinom | Nachrichten

Adjuvante Brustkrebstherapie: Doppelt hält besser

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

10.04.2024 | PSA-Screening | Nachrichten

Einladung zum PSA-Screening senkt die Krebssterblichkeit
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen